Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: Insights into factors associated with dose escalation

International Urogynecology Journal

Volumn 23, Issue 11, 2012, Pages 1581-1590

  Cardozo, Linda ^a   Hall, Timothy ^b   Ryan, John ^c   Bitoun, Caty Ebel ^d   Kausar, Imran ^e   Darekar, Amanda ^e   Wagg, Adrian ^f  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b Knowle House Surgery   (United Kingdom)

^c Alverton Practice   (United Kingdom)

^d PFIZER INC   (United States)

^e PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^f UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antimuscarinic; Fesoterodine; Flexible dosing; Overactive bladder

Indexed keywords

EID: 84868347916     PISSN: 09373462     EISSN: 14333023     Source Type: Journal    
DOI: 10.1007/s00192-012-1804-1     Document Type: Article

References (26)

1. Milsom I, Irwin DE (2007) A cross-sectional, population-based, multinational study of the prevalence of overactive bladder and lower urinary tract symptoms: results from the EPIC study. Eur Urol Suppl 6:4-9 (Pubitemid 44821939)
2. Reeves P, Irwin D, Kelleher C, Milsom I, Kopp Z, Calvert N et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050-1057 (Pubitemid 44486484)
3. Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC et al (2009) Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 19:380-394
4. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543-562
5. Novara G, Galfano A, Secco S, D'Elia C, Cavalleri S, Ficarra V et al (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740-763
6. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276-1282
7. Carr LK (2008) Overactive bladder. Can J Urol 15(Suppl 1):32-36; discussion 36
8. Michel MC, Staskin D (2011) Understanding dose titration: overactive bladder treatment with fesoterodine as an example. Eur Urol Suppl 10:8-13
9. Chapple CR, Rosenberg MT, Brenes FJ (2009) Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome. BJU Int 104:960-967
10. Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U et al (2007) Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 52:1204-1212 (Pubitemid 47332062)
11. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U et al (2007) Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 178:2488-2494 (Pubitemid 350052177)
12. Khullar V, Rovner ES, Dmochowski R, Nitti V, Wang J, Guan Z (2008) Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 71:839-843
13. Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z et al (2009) Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an openlabel study. Int J Clin Pract 63:560-567
14. Dmochowski RR, Peters KM, Morrow JD, Guan Z, Gong J, Sun F et al (2010) Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. Urology 75:62-68
15. Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR (2011) Validation of the urinary sensation scale (USS). Neurourol Urodyn 30:360-365
16. Coyne KS, Matza LS, Kopp Z, Abrams P (2006) The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 49:1079-1086 (Pubitemid 43673993)
17. Cardozo L, Coyne KS, Versi E (2005) Validation of the Urgency Perception Scale. BJU Int 95:591-596 (Pubitemid 40311479)
18. Coyne K, Revicki D, Hunt T, Corey R, Stewart W, Bentkover J et al (2002) Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 11:563-574 (Pubitemid 34876130)
19. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S (1997) A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 104:1374-1379 (Pubitemid 27517634)
20. Reese PR, Pleil AM, Okano GJ, Kelleher CJ (2003) Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder. Qual Life Res 12:427-442 (Pubitemid 36609887)
21. Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P (2004) ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn 23:322-330 (Pubitemid 38859423)
22. Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ (2005) The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue-the BSW. Value Health 8:S25-S34 (Pubitemid 43110283)
23. Piault E, Evans CJ, Espindle D, Kopp Z, Brubaker L, Abrams P (2008) Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 27:179-190 (Pubitemid 351399306)
24. Brubaker L, Khullar V, Piault E, Evans CJ, Bavendam T, Beach J et al (2011) Goal attainment scaling in patients with lower urinary tract symptoms: development and pilot testing of the Self-Assessment Goal Achievement (SAGA) questionnaire. Int Urogynecol J 22:937-946
25. Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Choo MS (2011) Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. BJU Int 107:603-611
26. Staskin D, Khullar V, Michel MC, Morrow JD, Sun F, Guan Z et al (2011) Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. Neurourol Urodyn 30:1480-1485